Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables

Özuysal, Sema; Öztürk, Hülya; Bilgin, Tufan; Filiz, Gülaydan

doi:10.1007/s00404-003-0595-5

Cited by 25 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several independent studies have shown the role of cyclin D1 in EC by examining the expression of cyclin D1 in normal endometrium, endometrial hyperplasia and EC. [15][16][17][18][19][20][21][22][23] A cyclin D1 polymorphism is associated with an increased risk of EC and may contribute to the development of this disease. 24,25 Although many upstream signaling molecules have been reported to upregulate cyclin D1, [26][27][28][29] little is known about factors that negatively regulate cyclin D1 abundance in EC cells.…”

Section: Introductionmentioning

confidence: 99%

Altered expression of DACH1 and cyclin D1 in endometrial cancer

Nan

Lü²,

Zhou³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

The altered expression of human DACH1, a Drosophila Dachshund homolog, has been associated with tumor progression and metastasis. DACH1 inhibits breast cancer cellular proliferation via cyclin D1. Endometrial cancer is the third most common cancer in women and broad screening for DACH1 expression will further our understanding of this disease. Herein, we screened 126 hysterectomy specimens for DACH1 expression and evaluated the correlation between DACH1 levels and several clinical parameters. Decreased DACH1 expression was significantly correlated with FIGO surgical stages (Stage I-II vs. stage III-IV, p = 0.017), peritoneal cytology (p = 0.044), lymph node positivity (p = 0.035) and histological type (p = 0.007), but not histological grade, depth of myometrial and patient age. Immunostaining was also conducted to examine the expression of cyclin D1, estrogen receptor alpha (ERα) and progesterone receptor (PR) in these specimens. Multivariate analysis using the stepwise Cox proportional hazard model showed that FIGO surgical stage, histological grade, lymph node metastasis, and PR expression were correlated with poor survival. Despite the fact that univariate analysis demonstrated that DACH1 positivity is associated with increased 5-year survival in all patients (p = 0.037), decreased expression of DACH1 had no significant value as an independent prognostic factor in predicting survival in endometrial cancers. Our results suggested that loss of DACH1 expression might be involved in endometrial cancer progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Altered expression of DACH1 and cyclin D1 in endometrial cancer

Nan

Lü²,

Zhou³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…For that reason, some morphometrical parameters, such as D score and the immunohistochemical aid method, have been tried for the differential diagnosis of endometrial carcinoma. [3][4][5][6][7][8]19 The ubiquitin-proteasome system plays an important role in regulating normal cellular processes. UbcH10 is the E2 ubiquitin-conjugating enzyme for the anaphase promoting complex, which coordinates mitosis and G1 by sequentially promoting the degradation of cell cycle regulators and plays a pivotal role in cell cycle progression.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, none of them are commonly used in the differential diagnosis of endometrial pathology. [3][4][5][6][7][8] Ubiquitin-dependent proteolysis is a physiological process related to cell cycle progression, differentiation, and signal transduction. 9 There are 3 different enzymes involved in this system: ubiquitin-activating enzyme (E1), ubiquitinconjugating enzyme (E2), and ubiquitin ligase (E3).…”

Section: Introductionmentioning

confidence: 99%

UbcH10 Expression in Benign, Hyperplastic, and Malignant Endometrial Curetted Materials

et al. 2012

View full text Add to dashboard Cite

The aim of this study was to investigate the role of UbcH10 expression in the differential diagnosis of benign, hyperplastic, and malignant endometrial tissues and also the relationship of UbcH10 with the clinicopathologic parameters of malignant cases. A tissue microarray was performed for 81 endometrial curettage biopsies, which histological diagnosis had demonstrated to be 13 cases of proliferative endometrium, 7 cases of disordered proliferative endometrium, 5 cases of complex atypical hyperplasia, 24 cases of nonatypical hyperplasia, and 32 cases of endometrioid adenocarcinoma. Expression of UbcH10 was assessed by immunohistochemistry. When groups were compared according to UbcH10 percentages and scores, a statistically significant difference was found only between the carcinoma group and the other groups, except the complex atypical hyperplasia group (P < .05). In the malignant group, UbcH10 percentages and scores were only significantly related to age. There was no significant association between UbcH10 expression and tumor grade and stage. Overexpression of UbcH10 may be a useful indicator of endometrial carcinoma. UbcH10 also deserves further evaluation in the detection of prognostic mean and also for its role in endometrial carcinogenesis.

show abstract

“…Recently, cellular markers (such as hormone receptors, angiogenesis, proliferative activity, and DNA ploidy), as well as molecular markers (such as Her-2/neu, and p53 proteins) are used as prognostic factors [22][23][24][25]. It is suggested that biologic markers are integral parts of the cellular cascade of events involved in tumor progression, and also parallel the clinical progression of metastatic disease.…”

Section: Discussionmentioning

confidence: 99%